The company behind renowned CBD brand Charlotte’s Web has teamed up with leading scientific researchers to examine the cannabinoid’s effects on physical and mental health.
Charlotte’s Web Labs (CWL), the research arm of the renowned CBD producer, has announced a long-term scientific collaboration with McLean Hospital, a Harvard Medical School affiliate.
Two distinct clinical trials will investigate the efficacy of a custom-formulated, hemp-derived high-CBD product, with results to be published in 2022.
The trials will be overseen by lead researcher Dr Staci A Gruber, Ph.D, associate professor of psychiatry at Harvard Medical School and director of the MIND program at McLean Hospital in Belmont, Mass.
Dr Gruber’s Marijuana Investigations for Neuroscientific Discovery (MIND) Program, established in 2014, is the first of its kind, and is dedicated to studying the long-term impact of cannabis and cannabinoids for medical and adult use which utilises various clinical and cognitive tools as well as multimodal neuroimaging techniques.
MIND utilises valid, robust research models and supports numerous projects designed to address the impact of medical cannabis on important variables such as cognition, brain structure and function, mood, conventional medication use, quality of life, pain, sleep, and other health-related measures.
Through observational longitudinal investigations, survey studies, and clinical trials of custom-formulated cannabinoid products, MIND aims to examine the unique effects of cannabis and its constituents to determine the efficacy of cannabinoids for specific conditions and diseases and to clarify the overall impact of cannabinoid-based treatments on physical and mental health.
Dr Gruber is also conducting a number of other studies, including a longitudinal observational study of veterans who use Charlotte’s Web products.
Charlotte’s Web is the number one CBD brand in the USA and distributed through more than 22,000 retail locations, select distributors and online.
CWL is the research and development division of Charlotte’s Web, with an aim of advancing science around hemp-derived phytocannabinoids, terpenes and flavonoid compounds.
“We are honoured to be working with Dr. Gruber, Harvard Medical School and McLean Hospital on these important clinical trials,” said Tim Orr, president of Charlotte’s Web’s CW Labs division.
“Charlotte’s Web remains dedicated to supporting third-party research on hemp CBD investigated by some of the country’s top scientists.”
- Malta gives green light to three new cannabis clubs
- European Commission must address ‘inequality’ in access to medicinal cannabis across EU
- 1 in 8 older US adults now use cannabis products, finds study
- 3 main contributors to the entourage effect for cannabis consumers to consider
- Medical cannabis doesn’t impair cognitive function – study
- Ukraine’s medical cannabis legalisation delayed by opponents
- News4 months ago
NHS approves major clinical trial on cannabis medicines and chronic pain
- News6 months ago
UK patient secures first NHS reimbursement for cannabis flowers
- Advocacy6 months ago
Inside a UK cannabis club: changing lives, tackling stigma, building community
- News4 months ago
UK research finds GP support for cannabis as an alternative to opioids for chronic pain
- Industry4 months ago
‘Landmark’ ruling gives hope for UK CBD flower businesses
- Industry6 months ago
New report calls for overhaul of ‘discriminatory’ UK cannabis driving laws
- News4 months ago
Malta: Advocates emphasise positive effects of cannabis reform amid ‘normalisation’ concerns
- Science4 months ago
Five new cannabis studies – ALS, epilepsy, Parkinson’s, chronic pain and blood pressure